title: [Corticosteroids in the management of advanced prostate cancer].
abstract: Corticosteroids have been widely used for decades in cancer therapy, predominantly due to their anti-inflammatory activity. In the treatment of metastatic castration-resistant prostate cancer (mCRPC), corticosteroids play an important role both in the management of tumor-related symptoms, especially bone metastasis-related pain, and as concomitant treatment to counteract side effects associated with approved active prostatic anticancer agents such as docetaxel, cabazitaxel, and abiraterone acetate. In association with abiraterone acetate, low-dose corticosteroids (prednisone or prednisolone) reduce the mineralocorticoid side effects of abiraterone. In addition, corticosteroids may exert direct antitumoral activities, resulting in PSA decline.
authors.affiliation: Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland. hubert.kuebler@tum.de.
authors.forename: H
authors.initials: H
authors.lastname: Kübler
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D010166:Palliative Care / Q000379:methods*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents
keywords: Abiraterone acetate; Antitumor effects; Castration-resistance; Chemotherapy; Corticosteroids; Palliation; Prostate cancer, metastatic